Thalidomide for treatment of patients with chronic graft-versus-host disease

Blood

Volumn 96, Issue 12, 2000, Pages 3995-3996

  Koc, S ^a   Leisenring, W ^a   Flowers, M E D ^a   Anasetti, C ^a   Deeg, H J ^a   Nash, R A ^a   Sanders, J E ^a   Witherspoon, R P ^a   Appelbaum, F R ^a   Storb, R ^a   Martin, P J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; PLACEBO; PREDNISONE; TACROLIMUS; THALIDOMIDE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034554783     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3995     Document Type: Article

References (8)

1. Thalidomide for graft-versus-host disease
2. Thalidomide for graft-versus-host disease after bone marrow transplantation
3. Thalidomide therapy of chronic graft-versus-host disease
4. Thalidomide treatment for chronic graft-versus-host disease
5. Therapy of chronic graft-v-host disease in a rat model
6. Thalidomide for the treatment of chronic graft-versus-host disease
7. Thalidomide as salvage therapy for chronic graft-versus-host disease
8. The statistical analysis of failure time data